SSA
SPRO icon

Schonfeld Strategic Advisors’s Spero Therapeutics SPRO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,314
Closed -$47.5K – 2980
2026
Q1 		$47.5K Buy
+20,314
New +$48.2K ﹤0.01% 1972
2025
Q3 		– Sell
-510,834
Closed -$1.48M – 2552
2025
Q2 		$1.48M Buy
+510,834
New +$735K 0.01% 1134
2018
Q4 		– Sell
-50,000
Closed -$526K – 1224
2018
Q3 		$526K Buy
+50,000
New +$580K 0.02% 569

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Schonfeld Strategic Advisors's SPRO Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 20,314 shares — an estimated $47.5K sold.

Schonfeld Strategic Advisors first reported a position in SPRO in Q3 2018 and held it in 3 quarters. The position peaked at $1.48M in Q2 2025. 59 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 20,314 Spero Therapeutics shares in Q2 2026, an estimated $47.5K.
  • Schonfeld Strategic Advisors first reported a position in Spero Therapeutics in Q3 2018 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Spero Therapeutics position peaked at $1.48M in Q2 2025.
  • 59 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.